We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Daiichi Sankyo Company Ltd (PK) | USOTC:DSNKY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.26 | 34.19 | 34.69 | 0.00 | 11:51:33 |
From Jun 2023 to Jun 2024
By Christian Moess Laursen
AstraZeneca said trial results for its breast cancer drug Dato-DXd showed significant improvement for the primary end-point of so-called progression-free survival in patients.
The Anglo-Swedish pharma giant said Friday the drug--fully-named datopotamab deruxtecan--showed a statistical significant and clinically meaningful improvement compared with chemotherapy in patients with breast cancer.
The safety profile of the treatment was consistent with previous clinical trials in breast cancer with no new safety signals identified, it said.
Progression-free survival means the length of time during and after treatment of a disease, such as cancer, a patient lives with the disease without it getting worse.
Dato-DXd is being jointly-developed with Japan's Daiichi Sankyo.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
September 22, 2023 02:38 ET (06:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Daiichi Sankyo (PK) Chart |
1 Month Daiichi Sankyo (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
